🇺🇸 FDA
Pipeline program

Sodium Oxybate

07I/C36-0

Phase 2 small_molecule completed

Quick answer

Sodium Oxybate for Schizophrenia is a Phase 2 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Jazz Pharmaceuticals plc
Indication
Schizophrenia
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials